Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
To maintain treatment blind, two different active patch sizes were used (10 cm\^2 \& 20 cm\^2). Placebo patches matched according to size and appearance. During the trial subjects applied up to three patches, active and placebo, to achieve their assigned daily dose.
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PD greater than 3 years
Stable dose L-dopa but symptoms not adequately controlled and have "off" time
Able and willing to complete diary on specific days
You may not be if
Previous use of rotigotine or Neupro
Atypical Parkinson's syndrome
Pallidotomy
Thalamotomy
Deep brain stimulation
Fetal tissue transplant
Dementia
Psychosis
Hallucinations
Epilepsy
Renal or hepatic dysfunction
Clinically relevant cardiac dysfunction
Symptomatic orthostatic hypotension
Skin sensitivity to adhesives or unresolved contact dermatitis
History of chronic alcohol or drug abuse
Pregnant or of child-bearing potential
Impulse control disorder
Clareo Health | Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
